{
  "title": "Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients",
  "description": "Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent <a href=\"https://www.npr.org/people/2100615/jon-hamilton\">Jon Hamilton</a> explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.<br/><br/>Additional links:<br/>- Jon's reporting on aducanumab: <a href=\"https://n.pr/3bDV0MY\">https://n.pr/3bDV0MY</a><br/>- Jon's reporting on future Alzheimer's treatments: <a href=\"https://n.pr/3bDUsqo\">https://n.pr/3bDUsqo</a><br/><br/>You can always reach the show by emailing <a href=\"mailto:shortwave@npr.org\">shortwave@npr.org</a>.",
  "pubDate": "Fri, 05 Nov 2021 00:30:56 -0400",
  "copyright": "Copyright 2019-2021 NPR - For Personal Use Only",
  "guid": "205ebcc8-308f-4e3e-aeaa-77f5f70d2397",
  "link": "https://www.npr.org/2021/11/03/1051989282/why-aduhelm-a-new-alzheimers-treatment-isnt-reaching-many-patients",
  "itunes:title": "Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients",
  "itunes:episode": 521,
  "itunes:author": "NPR",
  "itunes:summary": "Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent <a href=\"https://www.npr.org/people/2100615/jon-hamilton\">Jon Hamilton</a> explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.<br/><br/>Additional links:<br/>- Jon's reporting on aducanumab: <a href=\"https://n.pr/3bDV0MY\">https://n.pr/3bDV0MY</a><br/>- Jon's reporting on future Alzheimer's treatments: <a href=\"https://n.pr/3bDUsqo\">https://n.pr/3bDUsqo</a><br/><br/>You can always reach the show by emailing <a href=\"mailto:shortwave@npr.org\">shortwave@npr.org</a>.",
  "itunes:image": "",
  "itunes:duration": 586,
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "content:encoded": "Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to improve patients' lives. NPR science correspondent <a href=\"https://www.npr.org/people/2100615/jon-hamilton\">Jon Hamilton</a> explains why doctors and patients aren't excited about the new drug and what it could mean for future Alzheimer's drugs.<br/><br/>Additional links:<br/>- Jon's reporting on aducanumab: <a href=\"https://n.pr/3bDV0MY\">https://n.pr/3bDV0MY</a><br/>- Jon's reporting on future Alzheimer's treatments: <a href=\"https://n.pr/3bDUsqo\">https://n.pr/3bDUsqo</a><br/><br/>You can always reach the show by emailing <a href=\"mailto:shortwave@npr.org\">shortwave@npr.org</a>.",
  "enclosure": ""
}